Personne
Anguraj Sadanandam
Cette personne n’est plus à l’EPFL
Publications associées (10)
A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics
Douglas Hanahan, Anguraj Sadanandam, Stephan Wullschleger, Ismaël Wafy
Seeking to assess the representative and instructive value of an engineered mouse model of pancreatic neuroendocrine tumors (PanNET) for its cognate human cancer, we profiled and compared mRNA and miRNA transcriptomes of tumors from both. Mouse PanNET tumo ...
Amer Assoc Cancer Research2015The consensus molecular subtypes of colorectal cancer
Douglas Hanahan, Krisztian Homicsko, Sarah Gerster, Paolo Angelino, Mauro Delorenzi, Anguraj Sadanandam, Xin Wang
Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression-based CRC classifications and facilitate clinical translation, we formed an international c ...
Nature Publishing Group2015Colorectal cancer classification with differential prognosis and personalized therapeutic responses
Douglas Hanahan, Anguraj Sadanandam
The present invention relates to gene sets, the expression levels of which are useful for classifying colorectal tumors and predicting disease-free prognosis and response of patients to specific therapies that are either novel or currently available in the ...
2015Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Anguraj Sadanandam, Shan Jiang
Activating mutations in KRAS are among the most frequent events in diverse human carcinomas and are particularly prominent in human pancreatic ductal adenocarcinoma (PDAC). An inducible Kras(G12D) driven mouse model of PDAC has established a critical role ...
Cell Press2014Reconciliation of classification systems defining molecular subtypes of colorectal cancer
Douglas Hanahan, Anguraj Sadanandam, Xin Wang
Recently we published two independent studies describing novel gene expression-based classifications of colorectal cancer (CRC). Notably, each study stratified CRC into a different number of subtypes: one reported 3 subtypes, whereas the second highlighted ...
Landes Bioscience2014A colorectal cancer classification system that associates cellular phenotype and responses to therapy
Douglas Hanahan, Krisztian Homicsko, Anguraj Sadanandam, Stephan Wullschleger
Colorectal cancer (CRC) is a major cause of cancer mortality. Whereas some patients respond well to therapy, others do not, and thus more precise, individualized treatment strategies are needed. To that end, we analyzed gene expression profiles from 1,290 ...
Nature Publishing Group2013Identification and Characterization of Poorly Differentiated Invasive Carcinomas in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis
Douglas Hanahan, Anguraj Sadanandam
Pancreatic neuroendocrine tumors (PanNETs) are a relatively rare but clinically challenging tumor type. In particular, high grade, poorly-differentiated PanNETs have the worst patient prognosis, and the underlying mechanisms of disease are poorly understoo ...
Public Library of Science2013Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation
Anguraj Sadanandam, Stephan Wullschleger
BACKGROUND: Our earlier reports demonstrated that membrane-bound semaphorin 5A (SEMA5A) is expressed in aggressive pancreatic cancer cells and tumours, and promotes tumour growth and metastasis. In this study, we examine whether (1) pancreatic cancer cells ...
Nature Publishing Group2012A Cross-Species Analysis of a Mouse Model of Breast Cancer-Specific Osteolysis and Human Bone Metastases Using Gene Expression Profiling
Background: Breast cancer is the second leading cause of cancer-related death in women in the United States. During the advanced stages of disease, many breast cancer patients suffer from bone metastasis. These metastases are predominantly osteolytic and d ...
2011Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Douglas Hanahan, Anguraj Sadanandam
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease. Overall survival is typically 6 months from diagnosis(1). Numerous phase 3 trials of agents effective in other malignancies have failed to benefit unselected PDA populations, although patients do ...
Nature Publishing Group2011